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ABSTRACT
The management of genital herpesvirus infections in pregnancy has seen many changes over the
past decade as we have continued to learn more about the epidemiology of the disease. This article
reviews these changes and highlights ongoing controversies. Clinical management schemes are
proposed based upon this most recent information. (C) 1994 Wiley-Liss, Inc.
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he management of genital herpesvirus infec-
tions in pregnancy continues to be a challenge
in the 1990s. Although much has been learned
about the natural history and pathophysiology of
this disease, many questions remain unanswered.
The purpose of this article is to review recent devel-
opments as well outline areas of controversy where
further investigation is needed. Finally, a manage-
ment scheme will be proposed incorporating our
best information to date on this challenging issue.
The estimated incidence of neonatal infection
from herpes simplex virus (HSV) ranges from
1/7,500 to 1/30,000 livebirths, with evidence of
increasing frequency as high as 1/2,000 to 1/3,500
livebirths over the past 2 decades. 2’3 These are
frequently life-threatening infections with more
than 40% of neonates dying or suffering from sig-
nificant neurologic sequelae despite the use of anti-
viral treatments. 4’5 Unfortunately, most cases of
neonatal infection are not currently preventable,
with 85% of HSV-infected infants born to asymp-
tomatic women. 4’6 The challenge for the future lies
in identifying these asymptomatic infectious women
in a reliable, timely, and cost-effective manner in
order to prevent a greater number of neonatal in-
fections.
NATURAL HISTORY
HSVs are double-stranded DNA viruses catego-
rized into 2 types based upon their immunologic
and clinical differences. Type (HSV-1) most com-
monly causes nongenital herpes infections, but may
be responsible for approximately 15% of genital
infections. 7’8 Type 2 (HSV-2) affects predominan-
tely the genital regions, but may also occasionally
cause orolabial lesions. Genital HSV-1 infections
present .less concern for maternal or neonatal com-
plications. Unfortunately, there is no reliable
method for differentiating these infections clini-
cally or by commercially available laboratory stud-
ies. It has also been noted that only 15-50% of
HSV- compared with 70-90% of HSV-2 genital
infections will recur, with more than 90% of the
recurrences being secondary to HSV-2.8-10
Recently, the advent of type-specific glycopro-
tein assays has allowed researchers to determine the
prevalence of seropositivity for HSV-2. This num-
ber varies by population, approaching 100% in
prostitutes. The rate of seropositivity in various
cohorts of patients in the United States is approxi-
mately 20-40%. 1’12 As many as 80% of these
patients do not recall a primary infection and repre-
sent asymptomatic primary infections.
12,3 Presum-
Address correspondence/reprint requests to Dr. Curtis R. Cook, Department of Obstetrics and Gynecology, University of
Louisville, Louisville, KY 40292.
Received February 18, 1994
Review Article Accepted April 22, 1994HERPES IN PREGNANCY COOK AND GALL
ably, some of these patients would have been in-
fected in a less symptomatic region such as the
cervix or upper vagina. Others probably had ame-
liorated primary infections secondary to the pres-
ence of protective antibodies from a prior nongeni-
tal herpes infection. Prospective studies have shown
an annual conversion rate to HSV-2 of 0.6% in
14 previously seronegative women.
HSV replication and dissemination occur by di-
rect cell-to-cell transmission. The presence ofHSV
antibodies does not prevent recurrences, but may
limit dissemination and viremia. The virus is
known to remain dormant in the dorsal root ganglia
from where it may reappear as asymptomatic shed-
ding or symptomatic clinical disease. It is not clear
what triggers these recurrences although correla-
tion has been noted with fever, trauma, stress, men-
struation, and immunosuppression. Pregnancy is
not felt to exacerbate the disease.
Clinically, HSV infections are categorized as
lst-episode primary, lst-episode nonprimary, or
recurrent. Primary infections occur without the
presence of previous antibodies to either HSV-1 or
HSV-2. First-episode nonprimary infections occur
ifeither antibody is already present, providing some
protection and blunting of symptoms. Finally, re-
current infections occur in individuals with a his-
tory of genital herpes.
Primary HSV infections provide the greatest
concern, particularly when they occur near the time
of delivery. Infants born to these mothers are be-
lieved to be at increased risk because of the lack of
protective maternal antibodies, the longer duration
of shedding larger viral loads, and the increased
rate of cervical involvement. More than 80% of
primary infections have associated cervical shed-
ding at delivery,
9 with a vertical transmission rate
of 40-80%.
15
Primary genital herpes infections are marked by
a 3-6 day incubation period after exposure. Vulvar
burning and pruritis usually precede the presence
of multiple vesicles that may involve the vulva,
vagina, and cervix. These lesions become shallow,
painful ulcers after 24-3 6 h before eventually crust-
ing over. There are usually in excess of 20 vesicles
that contain between 0.5-1 million viral particles/
vesicle.
16 Lesions persist for an average of 19.7
days with viral shedding for 11.8 days on average.
More than 2/3 ofthese individuals will have consti-
tutional flu-like symptoms which may include re-
ver and painful lymphadenopathy.
9 Antibodies to
HSV are noted about 7 days following the onset of
primary infection and peak in 2-3 weeks. Infected
patients then remain seropositive for life.
Rarely, individuals may develop disseminated
disease including meningitis, hepatitis, encephali-
tis, and pneumonitis. Herpes meningitis has been
noted in approximately 4-8% of primary infections
with other visceral involvement being much less
commonly noted.
17 Overall, these can be quite se-
rious infections with maternal and neonatal mortal-
ities in excess of 50%. Recently, the use of systemic
antiviral agents such as acyclovir has resulted in
improved maternal and neonatal outcomes for these
18 severe cases.
Primary infections have been associated with an
increased rate of preterm delivery,
is Indeed, 50%
of HSV-infected infants are born premature. Of
the women with primary infections, 80% will be
expected to have 2- recurrences during preg-
nancy.
19-21 Many of these recurrences will be as-
ymptomatic, which underscores the current clinical
dilemma.
First-episode nonprimary infections are less
symptomatic due to the protective effect of HSV
antibodies. These infections occur less commonly
than primary infections. On average, these lesions
persist for 15.5 days and continue to shed virus for
6.8 days. Only 16% of these cases are expected to
demonstrate systemic symptoms.
9
Recurrent HSV infections comprise the great
majority of infections occurring at the time of de-
livery. The management of these patients remains
the most controversial, as is noted later in this
article. Recurrent infections are associated with vi-
ral shedding only 12-15% of the time. 9’2’21 The
vertical transmission rate is estimated at less than
5%.
1,22,23 This is apparently secondary to the pro-
tection of maternally acquired antibodies and the
presence of a decreased viral inoculum. Recurrent
infections have not been associated with an increased
risk for preterm labor.
19-21 Lesions persist for an
average of 9.3 days with viral shedding for an
average of 3.9 days. These lesions are fewer in
number and generally less painful. Systemic symp-
toms occur in less than 10% and disseminated cases
are extremely rare.
9 Recurrences are noted more
frequently late in pregnancy, but unfortunately have
no predictable correlation to viral shedding.
24-26
Antibody titers do not rise significantly with recur-
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rences and are therefore not helpful in confirming
these events.
DIAGNOSIS
The "gold standard" for diagnosis of HSV infec-
tions is still isolation by viral culture. Most cul-
tures will be positive by 48-72 h with a sensitivity
of 90-95%, although 7-10 days are necessary to
confirm a negative result. Even culture becomes
less than 50% sensitive if the lesions are already
crusted over.
27 For this reason, it is preferable to
culture lesions early in the vesicular or ulcerative
stage. Other tests have been developed including
monoclonal antibody tests and enzyme-linked im-
munosorbent assays (ELISA). These alternative
tests perform best in high-prevalance populations,
but still lack the sensitivity and specificity of viral
culture. Cytologic evaluation using the Papanico-
laou smear or the Tzanck preparation for the pres-
ence of intranuclear inclusions or multinucleated
giant cells has also been used for rapid evaluation.
This is helpful when positive, but is limited by its
relatively low sensitivity and high false negative
rate. Recently, investigators have used polymerase
chain reaction (PCR) to isolate viral fragments.
28
The ability to distinguish type-2 glycoprotein G has
11--13 allowed virotyping for research purposes.
However, no reliable commercial assay is avail-
able.
29
NEONATAL OUTCOMES
Neonatal I--ISV infections can be life-threatening
events with significant ocular and neurologic se-
quelae. These sequelae include microophthalmia,
retinal dysplasia, chorioretinitis, microcephaly,
mental retardation, seizure, apnea, and coma. In-
fections usually arise from direct contact with the
virus during passage through the birth canal or
from ascending infections after rupture ofthe mem-
branes. Approximately 10% of cases arise postna-
tally from direct contact with parents or caretakers
after delivery.
4 Less commonly, infections may oc-
cur as congenital infections after transplacental pas-
sage of the virus. 3’31
Neonatal infections may be disseminated, local-
ized, or asymptomatic. Disseminated illness more
frequently follows primary infections and may have
a 50-60% mortality with serious neurologic se-
quelae in 50% ofsurvivors.
5 Infections with I--ISV-2
appear to be associated with a worse prognosis.
32
The prognosis also appears to be worsened by delay
in the initiation of antiviral agents.
4 Localized in-
fections usually involve the eyes, skin, or mucous
membranes and tend to do well, although long-
term morbidities may result. Some infants remain
asymptomatic throughout the neonatal period.
Higher levels of neutralizing antibodies have been
demonstrated in the amniotic fluid and cord bloods
of the less symptomatic infants.
33
Intrauterine transplacental infections are respon-
sible for approximately 5% of the infections and
carry a mortality rate of 30%.
3 These infections
are marked by early symptoms of skin scarring,
rash, microophthalmia, chorioretinitis, microceph-
aly, and intrauterine growth restriction. Amnio-
centesis has not been effective in predicting these
infections. Because of the rarity of these infections,
therapeutic abortions are not recommended for pri-
mary genital herpes infections occurring in the st
trimester.
Overall, infected infants are expected to demon-
strate symptoms by 1-2 weeks of life with some
cases not presenting until 4-6 weeks of age. Typi-
cal symptoms are nonspecific and include seizure,
lethargy, irritability, temperature instability, poor
feeding, and skin manifestations. Antiviral agents
have been effective if initiated early. One recent
analysis calculated an overall mortality of 18.3%
with severe sequelae in 15.4% and moderate se-
quelae in 10.1% with recovery in 56.2% of in-
fected infants.
34 The Collaborative Antiviral Study
Group reported morbidities and mortalities of 17%
and 60% in disseminated disease, 67% and 14% in
isolated central nervous system (CNS) disease, and
8% and 0% in disease localized to the portal of
35 entry.
CLINICAL MANAGEMENT
Until the mid-1980s, the usual practice to identify
infectious women in labor was to perform weekly
herpes cultures of the lower genital tract in those
women with a history of genital herpes. Cesarean
delivery was then recommended for those women
with positive cultures near the time of partuition or
with lesions present in labor. Such surveillance
cultures were subsequently shown to be ineffective
in predicting the presence of virus at delivery in
asymptomatic women. 22’26 In addition, these cul-
tures were estimated to cost $1.8 million/case of
neonatal herpes averted.
36 For these reasons, the
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Infectious Disease Society for Obstetrics and Gyne-
cology recommended the abandonment of surveil-
lance cultures as well as amniocentesis to predict the
presence ofvirus at delivery. Cesarean delivery was
still recommended for the presence of lesions or
prodromal symptoms in labor.
37 The limitations of
this recommendation were recognized including the
inability to prevent transplacental infections and to
detect asymptomatic cervical shedding.
Obstetricians are still frustrated by the inability
to prevent more cases o neonatal herpes through
the use of cesarean deliveries. Currently, 20-30%
of neonatal infections occur in infants delivered by
cesarean section. 4’6 Some of these may have oc-
curred as a result of ascending infections after rup-
ture of the membranes. However, 8% of neonatal
infections occur despite cesarean delivery with in-
tact membranes.
6 The biggest challenge still re-
mains in identifying the 8 5% of neonatal infections
resulting from asymptomatic shedding. We are still
without a sensitive, timely, and inexpensive screen-
ing test to apply to the general pregnant population
in order to identify these high-risk women.
With these limitations, the most prudent ap-
proach emphasizes identifying those women with
the highest risk for cervical shedding at delivery in
order to minimize contact between the fetus and the
virus. This approach would include eliciting a his-
tory of genital herpes from either partner and con-
firming new lesions with HSV cultures if not pre-
viously documented. Surveillance cultures should
be abandoned unless used to demonstrate the ab-
sence of virus rom a late-trimester primary infec-
tion. Patients should be asked to present early after
rupture of the membranes and should be examined
carefully for the presence of external genital lesions
while in labor. Visual inspection has not proved
beneficial for detecting cervical or vaginal lesions.
Cesarean delivery is still recommended if lesions
are noted in labor regardless of the length of mem-
brane rupture. In the absence of documented le-
sions or prodrome, vaginal delivery may be at-
tempted regardless of a history of genital herpes.
Procedures that may allow additional portals of
entry such as scalp electrodes and scalp sampling
should be avoided, if possible, but are not contrain-
dicated in the absence of lesions.
Neonates should be initially isolated, cultured,
observed, and possibly treated with acyclovir if a
sufficient index of suspicion exists. Mothers need
not be isolated from their infant or other patients.
Mothers should practice thorough handwashing and
avoid infant contact with lesions. Breastfeeding may
be allowed as long as there are no lesions on the
breast. Prolonged in-hospital observation is not felt
necessary in the absence of a positive neonatal cul-
tue or unusual symptoms...These mothers need to be
educated about presenting neonatal symptoms and
need to report immediately any skin lesions or men-
tal status changes. Mothers with a history of genital
herpes should be aware of the small risk for neona-
tal infection even if they are asymptomatic at deliv-
ery.
CURRENT CONTROVERSIES
There still remain several controversial areas within
the management of genital herpes in pregnancy.
The st involves the use of antiviral agents. Acyclo-
vir, a specific viral DNA polymerase inhibitor, has
been demonstrated to reduce the duration of symp-
toms in nonpregnant primary infections. It has also
been shown to reduce the severity and number of
recurrences in nonpregnant patients. Its use is not
currently recommended in pregnancy unless dis-
seminated disease exists. However, acyclovir has
been used in hundreds of pregnant women without
adverse fetal outcomes. 38’9 Its use has been pro-
posed to attempt reduction in herpes recurrences
and subsequent cesarean delivery for this indica-
tion. Preliminary data have been promising in this
regard;4’41 however, this therapy may still not
prevent asymptomatic viral shedding and potential
neonatal inection.
42 Furthermore, the use of acy-
clovir may delay the humoral response to I--ISV,
thereby preventing or reducing passive immuniza-
tion of the ’etus.
4 At this time, acyclovir cannot be
recommended except in research protocols and in
cases of life-threatening disseminated illness. Of
course, acyclovir will continue to be used in neo-
nates and nonpregnant patients.
Second, the management of premature rupture
ofthe membranes (PROM) in the presence ofHSV
lesions also remains an area of controversy. Case
reports and case series have demonstrated the possi-
bility of expectant management in preterm
PROM. 44’45 In the largest reported series of 18
patients, 3 patients suffered additional recurrences
during their latency period. Eight patients were
delivered by cesarean section for the presence of
lesions at the time of indication for delivery. None
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of the 18 infants developed neonatal HSV infec-
tions, although some of the mothers were treated
with acyclovir antepartum.
45 Based on these lim-
ited data, it would seem reasonable to perform ce-
sarean deliveries if" at or near term and otherwise to
manage the remote-from-term patient expectantly
unless delivery is indicated. There are still insuffi-
cient data to recommend the antepartum use of
acyclovir.
Previously, it had been recommended to per-
form a cesarean delivery within 4-6 h of rupture of
the membranes at term. A vaginal delivery was
allowed if ruptured beyond this period of time.
This recommendation was based on 2 small patient
series that demonstrated no infections if" ruptured
for fewer than 4 h with significant infections de-
spite cesarean delivery if ruptured beyond this
point. 46’47 Unfortunately, subsequent data have
demonstrated infections even ifthe membranes were
intact or ruptured fewer than 4 h. Additionally,
prolonged latency periods do not ensure neonatal
infection. 44’4s Therefore, it still seems prudent to
perform cesarean deliveries in the presence of le-
sions in labor regardless of the length of membrane
rupture.
Third, another area of controversy involves the
intrapartum management of lesions away from the
birth canal. Lesions involving distal locations such
as the thigh and buttock have been associated with
neonatal infections. However, the risk of concur-
rent cervical shedding is very |OW. 21’25 For this
reason, it would seem reasonable to allow vaginal
delivery with covering of distal lesions to prevent
neonatal contact.
Fourth, the recommendation of the Infectious
Disease Society for Obstetrics and Gynecology to
obtain maternal cultures at delivery in asymptom-
atic women with a history of genital herpes remains
controversial.
37 This was initially proposed in or-
der to guide further neonatal therapy. Unfortu-
nately, cultures are less sensitive in this group of
women because of the decreased viral load. Addi-
tionally, few infants exposed to this clinical situa-
tion will develop neonatal infection. This brings
into question the cost-benefit of this approach. It
would seem more reasonable to culture women with
lesions at delivery and neonates at increased risk for
exposure to cervical shedding.
Finally, the most recent area of controversy in-
volves the delivery management of patients with
recurrent rather than primary infections. These in-
fections make up the vast majority of genital infec-
tions occurring at the time of delivery. There is
good evidence to support the premise that we have
overestimated the risk of cervical shedding and
subsequent neonatal infection in the patients with
recurrent infections.
2 +dditionally, it has been
recently estimated that our current management of
these patients would cost $2.5 million/case of neo-
natal infection averted.
34 In this same decision anal-
ysis, an estimated 1,5 8 0 cesarean sections and 0.57
maternal deaths would occur to prevent each case of
neonatal infection in women with recurrent genital
herpes. In contrast, only 9 cesarean sections and
0.004 maternal deaths would occur in cases of
women with primary genital herpes infections. This
would result in an overall cost savings of $38,000/
case of neonatal infection averted in these primary
infections.
4 While this study is provocative, there
are some limitations of concern in the analysis.
Several of the assumptions made were classified as
"low level of confidence" or "best guess" because of
a paucity of data. This information should, how-
ever, generate further discussion and evaluation of
our management of this group of patients with
recurrent genital herpes infections. Furthermore,
it now seems justifiable to pursue randomized trials
of delivery management for patients with recurrent
infections if patients and practitioners can be con-
vinced to participate.
CONCLUSIONS
We have learned much about the natural history
and pathophysiology of genital herpes infections in
pregnancy over the past 2 decades. However, many
questions remain unanswered. How do we effec-
tively screen for asymptomatic cervical shedding in
a reliable and cost-effective manner? How do we
best manage the patient with a history of genital
herpes and recurrent lesions in labor? What, if any,
therapies are effective in reducing vertical trans-
mission? These and other questions will continue to
be areas of active research. Until such time that
answers to these and other questions are available,
we will continue to focus on identifying the patient
at greatest risk for cervical shedding in labor and
attempt to minimize neonatal contact with such
shedding.
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